Inhalation Sciences (ISAB) has announced that it will divest 40,000 shares of its subsidiary Ziccum AB in order to finance a study to validate its PreciseInhale dosing system for clinical use. The company said that it anticipates achieving technical and regulatory validation in approximately 15 months.
PreciseInhale, which can produce aerosols at a specified dose and particle size distribution, is currently in use for pre-clinical development. ISAB said that in pre-clinical studies, “ISAB has successfully delivered clear indications of IVIVC, or in vitro in vivo correlation, when pre-clinical data generated by its pre-clinical modules including DissolvIt have proved to accurately predict subsequent clinical findings.” According to the company’s website, DissolvIt “enables in vitro simulation of absorption and dissolution of respirable particles in the lung epithelium.”
ISAB CEO Lena Heffler commented, “A major advantage of carrying out the study ourselves is that we then own the data generated, and can use it in future publications, marketing and commercialization. Building on the research projects we recently carried out in collaboration with one of the leading companies in the inhalation industry, we assess the prospects of being able to successfully develop PreciseInhale for further clinical use as very good.”
Read the ISAB press release.
